Retinal ciliopathy

Retinal ciliopathy is a group of inherited retinal dystrophies caused by dysfunction of the primary cilium in photoreceptor cells of the retina. Primary cilia are essential cellular structures required for the proper development and function of photoreceptors, and mutations in genes encoding ciliary proteins lead to progressive degeneration of these cells. Retinal ciliopathies encompass a broad spectrum of conditions including retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy, and Bardet-Biedl syndrome-associated retinal degeneration, among others. The primary body system affected is the visual system, though in syndromic forms, other organs such as the kidneys, brain, and skeletal system may also be involved. Key symptoms of retinal ciliopathy include progressive loss of vision, night blindness (nyctalopia), loss of peripheral visual fields, decreased visual acuity, and photophobia. In many cases, the condition begins with rod photoreceptor dysfunction leading to difficulty seeing in dim light, followed by progressive cone involvement resulting in loss of central vision and color vision deficits. The severity and rate of progression vary widely depending on the specific genetic cause. Fundoscopic examination may reveal characteristic findings such as bone-spicule pigmentation, attenuated retinal vessels, and optic disc pallor. Currently, there is no universal cure for retinal ciliopathies. Management is largely supportive and includes low-vision aids, orientation and mobility training, and regular ophthalmologic monitoring. Gene therapy has emerged as a promising treatment avenue, with voretigene neparvovec (Luxturna) approved for RPE65-associated retinal dystrophy, representing a landmark advance for one specific genetic subtype. Clinical trials investigating gene therapy and other molecular approaches for additional ciliopathy-related genes are ongoing. Genetic testing is strongly recommended to identify the causative mutation, which can guide prognosis, family counseling, and eligibility for emerging therapies.

Common questions about Retinal ciliopathy